Using beetroot juice to prevent kidney damage during heart procedures
Suplementación Con Zumo de REmolacha Para Prevenir la Nefropatía Asociada a Contraste Durante la hospitalización Por Síndrome Coronario Agudo Sin elevación Del ST
This study is testing if drinking beetroot juice can help protect the kidneys of patients at high risk for kidney damage during heart procedures.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 130 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospital General Universitario Santa Lucia Academic / other |
| Locations | 1 site (Cartagena) |
| Trial ID | NCT06695429 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of beetroot juice supplementation in preventing contrast-induced nephropathy in patients hospitalized for non-ST elevation acute coronary syndrome who are at high risk for kidney injury. Participants will be divided into two groups: one receiving beetroot juice along with standard care, and the other receiving standard care alone. The intervention involves consuming 500 mL of beetroot juice daily for seven days or until discharge, while both groups will receive additional therapies to prevent kidney damage if needed. The study seeks to determine if the inorganic nitrates in beetroot juice can protect kidney function during cardiac catheterizations.
Who should consider this trial
Good fit: Ideal candidates are adults diagnosed with non-ST elevation acute coronary syndrome who are at moderate to high risk for contrast-induced nephropathy.
Not a fit: Patients with persistent ST segment elevation acute coronary syndrome or those on dialysis may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence of kidney damage in patients undergoing heart procedures.
How similar studies have performed: Previous studies have shown promising results with inorganic nitrates in preventing contrast-induced nephropathy, but this specific approach using beetroot juice is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of Acute Coronary Syndrome without persistent ST segment elevation, with recommendation for invasive management according to the actual Clinical practice guidelines * At least moderate or high risk of nephropathy associated with iodinated contrast (Mehran score (without including contrast volume) ≥ 6). Exclusion Criteria: * \<18 years old or without capacity to give consent. * Refusal to participate in the study. * Known hypersensitivity to beetroot or any of its allergens. * Pregnant. * Inability to take food orally * Serious illnesses (not related to ACS or kidney failure), which limits their life expectancy to a period predictably less than 1 year. * On dialysis or predialysis at the time of inclusion. * ACS with persistent ST segment elevation before inclusion. * Shock or inotrope dependence at the time of inclusion * PCI already performed before inclusion. * Patients receiving intravenous nitroglycerin for \> 1 hour before inclusion
Where this trial is running
Cartagena
- Hospital Universitario Santa Lucía — Cartagena, Spain (Recruiting)
Study contacts
- Study coordinator: Jose Manuel Andreu Cayuelas, PhD
- Email: jmandreu@msn.com
- Phone: +34 968 12 86 00
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.